My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail vetinfo@hpra.ie

CANIXIN DHPPi lyophilisate and solvent for suspension for injection for dogs

Virbac S.A.VPA10988/101/001

Main Information

Trade NameCANIXIN DHPPi lyophilisate and solvent for suspension for injection for dogs

Active SubstancesCanine distemper virus (lederle strain)
Canine parvovirus (cpv 780916 strain)
Canine adenovirus type 2 (manhattan strain)
Canine parainfluenza (manhattan strain)

Dosage FormLyophilisate and solvent for suspension for injection

Licence HolderVirbac S.A.

License Holder Address1ère avenue
2065 M LID
06516 Carros
France

Licence NumberVPA10988/101/001

Group Information

ATC CodeQI07AD04 canine distemper virus + canine adenovirus + canine parvovirus + canine parainfluenza virus

Therapeutic ClassImmunological - Live Vaccine

SpeciesDogs

Status

License statusAuthorised

Licence Issued16/09/2016

Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation

Documents

Summary of Product Characteristics *PDF Version

Package LeafletNo document available

Public Assessment ReportNo document available

VariationsPDF Version

* The PDF document, together with the national-specific product information on this page, constitute the authorised SPC

« Back

Follow medicine

Print